UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): ~~September~~May 822, ~~2022~~2023

~~Artemis Therapeutics~~Manuka, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware		000-24431		84-1417774
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)

3 Eliezer Vardinon St., Petach Tikva, Israel		4959507
(Address of Principal Executive Offices)		(Zip Code)

(646) 233-1454

(Registrant’s telephone number,

including area code)

~~Not~~Artemis ~~applicable~~Therapeutics, Inc.

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Section Act (17 CFR 230.425).

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240-14d-2(b)).

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.01 per share	ATMS	OTC Pink Open Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On ~~September~~May 818, ~~2022~~2023, Manuka, Inc. (formerly known as Artemis Therapeutics, Inc., or (the "Company”)), filed a Certificate of Amendment (the “Certificate of Amendment”) to ~~the~~its Certificate of Incorporation, ofas ~~the~~amended, ~~Company~~ with the ~~Secretary of~~ State of ~~the~~Delaware ~~State~~Division of ~~Delaware,~~Corporations orto ~~the~~change ~~Certificate~~its ofcorporate ~~Amendment,~~name ~~pursuant~~ to ~~which~~Manuka, ~~the~~Inc. ~~Company~~A ~~increased~~copy ~~the number~~ of ~~authorized~~the ~~shares~~Certificate of ~~common stock~~Amendment ~~from~~is ~~51,000,000~~filed toas ~~150,000,000,~~Exhibit ~~or the Authorized Capital Change~~3.1 ~~The~~hereto ~~Authorized~~and incorporated ~~Capital~~herein ~~Change~~by ~~took effect on September 8, 2022~~reference.

~~The~~Item ~~Board~~9.01 ofFinancial ~~Directors~~Statements ~~approved the Authorized Capital Change on July 25, 2022~~ and ~~the holders of a majority of the Company’s outstanding common stock approved the Authorized Capital Change on July 27, 2022~~Exhibits.

The foregoing description of the Certificate of Amendment does not purport to be complete and is qualified in its entirety by reference to the full text of the Certificate of Amendment, a copy of which is filed as Exhibit 3No.1 ~~hereto and incorporated by reference herein.~~Description

Item 9.01. Financial Statements and Exhibits.

3.1	Certificate of Amendment to the Company's Amended and Restated Certificate of Incorporation, dated May 18, 2023
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

(d) Exhibits

Exhibit No.		Description
3.1		Certificate of Amendment, dated September 8, 2022
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

	ARTEMIS THERAPEUTICS, INC.
	MANUKA, INC.
Dated: September 9, 2022	By:	/s/ Shimon Citron
Dated: May 22, 2023	By:	/s/ Shimon Citron
	Name:	Shimon Citron
	Title:	Chief Executive Officer

Filing Compare · Manuka, Inc.